Combination Of Antigens From Multiple Viral Species (e.g., Multivalent Viral Vaccine, Etc.) Patents (Class 424/202.1)
-
Patent number: 8444997Abstract: The present invention relates to a vaccine composition against feline calicivirus (CFV) infection. The composition comprises a capsid protein of Feline calicivirus-49 (CFV-49), a pharmaceutical accepted carrier and optionally an adjuvant. The present invention further relates to a feline vaccine composition further comprises other live, attenuated or inactivated CVF component in addition to the capsid protein of FCV-49. The present invention also relates to a method for making or using the vaccine compositions.Type: GrantFiled: June 28, 2010Date of Patent: May 21, 2013Assignee: Zoetis LLCInventors: David E. Lowery, Sing Rong, Paul M. Guimond, Paula M. Clare, Cassius M. Tucker, Thomas Jack Newby
-
Patent number: 8440203Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.Type: GrantFiled: November 6, 2009Date of Patent: May 14, 2013Assignee: Intervet Inc.Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
-
Patent number: 8414899Abstract: The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.Type: GrantFiled: April 11, 2007Date of Patent: April 9, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Hila Amir-Kroll, Noam Cohen, Gabriel Nussbaum
-
Patent number: 8398992Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.Type: GrantFiled: December 22, 2011Date of Patent: March 19, 2013Assignee: Polytopos LLCInventors: Michael W Deem, Jeong-Man Park, Hao Zhou
-
Publication number: 20130064848Abstract: Heterochain aliphatic poly-N-oxide copolymers of general formula (1), where R?N, CH; x=2 or 4; y=0 or 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n, exhibit pharmacological activity, including an antioxidant effect and a therapeutic effect as a detoxicant and immunomodulating agent. The copolymer may be used as vaccinating agent also comprising an antigen and a vaccine against hepatitis A and hepatitis B, which contains a vaccine preparation comprising HVA Ag and HBsAg simultaneously or vaccine preparations against hepatitis A and against hepatitis B. The invention represents a new class of compounds that exhibit a wide range of pharmacological activity and a vaccination effect as well as increased safety in use, and is directed towards increasing manufacturability, cost efficiency and environmental safety in the production of drugs.Type: ApplicationFiled: June 20, 2011Publication date: March 14, 2013Inventors: Arkady Vasilievich Nekrasov, Natalya Grigoryevna Puchkova
-
Patent number: 8372409Abstract: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided.Type: GrantFiled: April 8, 2004Date of Patent: February 12, 2013Assignee: University of Florida Research Foundation, Inc.Inventor: Mansour Mohamadzadeh
-
Patent number: 8354114Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics.Type: GrantFiled: October 17, 2006Date of Patent: January 15, 2013Assignee: Medimmune, LLCInventors: Bin Lu, Hong Jin
-
Publication number: 20130011433Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: ApplicationFiled: November 28, 2011Publication date: January 10, 2013Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
-
Publication number: 20120328651Abstract: The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.Type: ApplicationFiled: June 21, 2012Publication date: December 27, 2012Inventors: Stefano Colloca, Alfredo Nicosia, Elisabetta Sporeno, Agostino Cirillo, Bruno Bruni Ercole, Annalisa Meola, Paolo Palazzolo
-
Patent number: 8337860Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: GrantFiled: August 15, 2007Date of Patent: December 25, 2012Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy
-
Patent number: 8337857Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.Type: GrantFiled: June 20, 2006Date of Patent: December 25, 2012Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Frederic Tangy, Marianne Lucas-Hourani, Erika Navarro-Sanchez, Marie-Pascale Frenkiel, Hugues Bedouelle, Chantal Combredet, Philippe Despres
-
Publication number: 20120321663Abstract: A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion.Type: ApplicationFiled: March 15, 2011Publication date: December 20, 2012Applicant: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPICInventors: Francois Bertrand, Sebastien Deville, Laurent Dupuis
-
Patent number: 8333975Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: December 16, 2011Date of Patent: December 18, 2012Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8333980Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.Type: GrantFiled: November 13, 2008Date of Patent: December 18, 2012Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
-
Patent number: 8323658Abstract: Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate.Type: GrantFiled: October 28, 2010Date of Patent: December 4, 2012Assignee: PAH W LLCInventors: Jeffrey Harold Rodenberg, Mahesh Kumar, Kalen Cookson
-
Patent number: 8323663Abstract: The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.Type: GrantFiled: May 8, 2008Date of Patent: December 4, 2012Assignee: GenVec, Inc.Inventors: Douglas E. Brough, Joseph T. Bruder, C. Richter King, Marvin J. Grubman, John G. Neilan
-
Publication number: 20120294891Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.Type: ApplicationFiled: May 21, 2012Publication date: November 22, 2012Applicant: University of Florida Research Foundation, Inc.Inventor: JANET K. YAMAMOTO
-
Publication number: 20120294889Abstract: The invention provides chimeric flavivirus vectors encoding one or more structural proteins from a first flavivirus with a low level of replication in a cell, such as dengue virus and yellow fever virus, and a backbone from a second flavivirus with a high level of replication in the cell, such as the Rio Bravo virus or the Uganda S virus. The chimeric flaviviruses encoded by the chimeric flavivirus vectors of the invention can be used to vaccinate subjects to prevent infection from infectious flaviviruses, including dengue viruses and yellow fever viruses.Type: ApplicationFiled: November 11, 2011Publication date: November 22, 2012Applicant: PAXVAX, INC.Inventors: Thomas P. Monath, Nikolaos Vasilakis
-
Publication number: 20120269848Abstract: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism are also included.Type: ApplicationFiled: June 18, 2012Publication date: October 25, 2012Inventors: George A. Scheele, James E. Hildreth
-
Patent number: 8288090Abstract: Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.Type: GrantFiled: January 19, 2010Date of Patent: October 16, 2012Assignee: Statens Serum InstitutInventor: Anders Fomsgaard
-
Publication number: 20120237543Abstract: The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Phillip Wayne HAYES, Kristina J. HENNESSY, Laurent VIEL, Andres DIAZ-MENDEZ
-
Publication number: 20120231033Abstract: The present invention relates to pharmaceutical compositions comprising an immunizing amount of inactivated Newcastle disease and an adjuvant for use in the protection of poultry against Newcastle disease, to the use of an immunogenic amount of an inactivated Newcastle disease virus and an adjuvant for the manufacture of a booster vaccine for the vaccination of a chicken or turkey, and to a kit-of-parts comprises a container comprising an inactivated Newcastle disease virus and an adjuvant for a priming vaccination of a chicken or turkey and a container comprising an inactivated Newcastle disease virus and an adjuvant for a boosting vaccination of a chicken or turkey.Type: ApplicationFiled: November 30, 2010Publication date: September 13, 2012Inventor: Carla Christina Schrier
-
Publication number: 20120207782Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: ApplicationFiled: July 18, 2011Publication date: August 16, 2012Applicants: University of Kansas Medical Center, National Institute for Agriculture ResearchInventors: Opendra Narayan, Euan Narayan, Yahia Chebloune
-
Publication number: 20120201848Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.Type: ApplicationFiled: October 14, 2010Publication date: August 9, 2012Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITYInventor: Sanjay Kapil
-
Publication number: 20120164170Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Inventors: Tsun-Yung KUO, Hsu Chung Gabriel Chen, Chung-Chin Wu, Han-Ting Chen
-
Publication number: 20120135034Abstract: This invention relates to non-integrating, non-replicating retroviral vectors that cause an immune response in an animal host when administered to the host. The vectors transduce cells in the host, where they produce virus-like particles (VLPs), which stimulate an additional immune response in the host when they are released from the cells. The vectors are non-integrating, non-replicating retroviral vectors comprising long terminal repeats, a packaging sequence, and a heterologous promoter operably linked to one or more polynucleotide sequences that together encode the structural proteins of a virus. Methods of making and using the vectors are also disclosed.Type: ApplicationFiled: March 13, 2010Publication date: May 31, 2012Inventor: Boro Dropulic
-
Publication number: 20120107345Abstract: When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.Type: ApplicationFiled: November 22, 2011Publication date: May 3, 2012Inventor: Mario Contorni
-
Publication number: 20120107348Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: January 9, 2012Publication date: May 3, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Patent number: 8168202Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.Type: GrantFiled: July 7, 2006Date of Patent: May 1, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Albert Z. Kapikian, Lone Simonsen, Timo Vesikari, Yasutaka Hoshino, David M. Morens, Robert M. Chanock, John R. La Montagne, Mary Elaine La Montagne, legal representative, Brian R. Murphy
-
Patent number: 8168772Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: GrantFiled: August 30, 2007Date of Patent: May 1, 2012Assignee: Altravax, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Patent number: 8163533Abstract: The present invention provides methods and compositions for rapidly producing multivalent recombinant vaccines using filamentous fungal heterokaryons. The present invention relies on the use of filamentous fungal heterokaryons that are generated from combinations of two or more parent strains into which recombinant DNA molecules encoding variants of antigens derived from pathogenic organisms have been introduced. The resulting vaccines are multivalent.Type: GrantFiled: October 17, 2005Date of Patent: April 24, 2012Assignee: Intrexon CorporationInventors: W. Dorsey Stuart, Edward B. Cambareri
-
Publication number: 20120093884Abstract: The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and rotavirus recombinant VP6 protein or double-layered VP2/VP6 VLPs. In addition, the invention relates to methods of inducing an immune response.Type: ApplicationFiled: October 7, 2011Publication date: April 19, 2012Inventors: Timo VESIKARI, Vesna BLAZEVIC, Kirsi NURMINEN, Leena HUHTI, Suvi LAPPALAINEN, Eeva JOKELA
-
Publication number: 20120064115Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.Type: ApplicationFiled: April 30, 2010Publication date: March 15, 2012Inventors: Corinne John, Christian Schaub, Sabine Wellnitz
-
Patent number: 8133712Abstract: Embodiments of the present invention provide an inactivated chimeric virus and immunogenic compositions for the treatment or prevention of infection with West Nile virus. Further, other embodiments of the present invention relate to methods of preventing and treating West Nile virus infection with the inactivated chimera or immunogenic composition.Type: GrantFiled: May 12, 2011Date of Patent: March 13, 2012Assignee: Intervet International B.V.Inventors: Frank J. Sterner, Daniel Ghislena Emiel Goovaerts, Melissa Anne Lum, Mark William Mellencamp
-
Publication number: 20120053509Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 6, HPV 11, HPV 33 and HPV58 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: ApplicationFiled: October 12, 2011Publication date: March 1, 2012Inventors: David B. WEINER, Jian YAN
-
Patent number: 8124398Abstract: The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.Type: GrantFiled: April 24, 2006Date of Patent: February 28, 2012Assignee: Sanofi Pasteur Biologics Co.Inventors: Konstantin V. Pugachev, Farshad Guirakhoo, Thomas P. Monath
-
Patent number: 8124105Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.Type: GrantFiled: June 23, 2009Date of Patent: February 28, 2012Assignees: The Trustees of the University of Pennsylvania, The United States of America as represented by the Department of Health and Human ServicesInventors: Gary H. Cohen, Roselyn J. Eisenbert, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
-
Patent number: 8119146Abstract: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The plasmids may also include: (3) a LEU2 selection marker; (4) a 2? plasmid sequence; and (5) an origin of replication functional in Escherichia coli. HBsAg can be expressed in this host, and can be purified for use in the manufacture of vaccines, and in particular for the manufacture of combination vaccines and in new monovalent HBV vaccines e.g. with non-alum adjuvants.Type: GrantFiled: April 14, 2006Date of Patent: February 21, 2012Inventor: Angelica Medina-Selby
-
Patent number: 8114410Abstract: Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a heptad portion of a Henipavirus F protein effective against fusion between a membrane of a paramyxovirus and a plasma membrane of a cell. The instant invention also provides nucleic acids, compositions, and methods effective against paramyxovirus infection. Accordingly, the instant invention provides therapeutic agents and vaccines effective against paramyxoviruses viruses, especially HeV or NiV.Type: GrantFiled: January 6, 2010Date of Patent: February 14, 2012Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Publication number: 20120034262Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.Type: ApplicationFiled: October 1, 2009Publication date: February 9, 2012Applicants: NOVARTIS AG, CORNELL UNIVERSITYInventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
-
Patent number: 8110196Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.Type: GrantFiled: April 29, 2005Date of Patent: February 7, 2012Assignee: Polytopas LLCInventors: Michael W. Deem, Jeong-Man Park, Hao Zhou
-
Publication number: 20120027795Abstract: Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein.Type: ApplicationFiled: May 10, 2011Publication date: February 2, 2012Inventors: Matti Sallberg, Lars Frelin, Magnus Johansson
-
Publication number: 20120014981Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: August 18, 2011Publication date: January 19, 2012Inventors: Richard M. Kinney, Claire Y.H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Publication number: 20120003240Abstract: Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond, Malin Flodstrom-Tullberg
-
Publication number: 20110318383Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DDI antigen.Type: ApplicationFiled: September 7, 2011Publication date: December 29, 2011Inventors: Chengjin HUANG, Jennifer Hess
-
Publication number: 20110305725Abstract: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS.Type: ApplicationFiled: March 9, 2011Publication date: December 15, 2011Applicant: WYETH LLCInventor: STEPHEN QITU WU
-
Publication number: 20110305726Abstract: The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses.Type: ApplicationFiled: August 7, 2009Publication date: December 15, 2011Applicant: Wyeth LLCInventors: Harmen Jacob Geerligs, Cindy Aleida Maria Meinders, Geert Jan Boelm, Bastiana Geertruida Elisabeth Stuurman
-
Patent number: 8075903Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: March 4, 2009Date of Patent: December 13, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
-
Patent number: 8071561Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: GrantFiled: August 15, 2008Date of Patent: December 6, 2011Assignee: ChronTech Pharma ABInventors: Matti Sallberg, Jonas Soderholm, Lars Frelin
-
Publication number: 20110293701Abstract: The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Lloyd Johnston, Grayson B. Lipford, Charles Zepp